Nanopatch is the vaccine delivery system for people who fear. Aug 26, 2014 vaxxas is a privatelyheld biotechnology company focused on enhancing the performance of existing and nextgeneration vaccines with its proprietary nanopatch technology platform. Nanopatch is the vaccine delivery system for people who fear needles. It is also one that, alongside clean water and sanitation, has played a key role in. Romars involvement in developing the nanopatch started 5 years ago at the conception stage. Feb 09, 2015 vaxxas is developing what its calling the nanopatch, a halfinch square, needlefree method of vaccinating that would also be easier to transport because it doesnt need refrigeration. It took 70 presentations before he secured funding for the university of queensland spinout company vaxxas, which now employs 50 people. Nanopatch technology is being commercialised by vaxxas pty ltd, which has scaled the nanopatch from use in small models to prototypes for human use. Vaxxas named technology pioneer for vaccine delivery device. The nanopatch is designed to place a tiny amount of vaccine just under the skin without the need for a needle jab. Vaxxas nanopatch on channel 7 news and today tonight. Mark kendall, inventor of the nanopatch smaller than a postage. Aug 26, 2014 vaxxas, which opened its local office two years ago and has its ceo here, was been named a 2015 technology pioneer today by the world economic forum for its potential to transform the future of.
Vaxxas initiates program with merck to optimize delivery of. An australian company is developing a piece of nano technology which. Nanopatch polio vaccine success uq news the university. Unlock charts on crunchbase charts can be found on various organization profiles and on hubs pages, based on data availability. The introduction of genetic engineering has fueled rapid advances in vaccine technology and is now leading to the entry of new products in the marketplace. Usability trials on the technology, nanopatch, including in papua new guinea, had been a key stepping stone towards the clinical trials, said university of queensland biomedical engineer mark. Nanopatch polio vaccine delivers, research indicates. Vaxxas inc company profile and news bloomberg markets. Efforts to rid the world of polio have taken another significant step, thanks to research led by university of queensland bioscience experts and funding from the world health organisation who. The makers of microneedle patches believe theyve found a replacement for traditional vaccines and acutemigraine treatments, but challenges remain. Feb 24, 2015 revolutionizing vaccination vaxxas secures funding to advance clinical development of the nanopatch, a painfree, needlefree vaccine application and delivery system.
This process will involve several rigorous testing phases to ensure the patch is effective and safe. Nanopatch is the vaccine delivery system for people who. At vaxxas today personnel are confident that we have a technology which is. Vaxxas is a company based out of vaxxas pty ltd acn 152 205 242c oneventures management suite 304, level 3, 1 alfred street, sydney, nsw, australia.
Qmnc is one inside griffith stories, news, views and video from the diverse griffith university community. Vaxxas hold patents over one of the world most exciting biotechnology products, the nanopatch, which is a safer, more reliable and durable delivery system for vaccines than needles. Jan 10, 20 the nanopatch is designed to place a tiny amount of vaccine just under the skin without the need for a needle jab. Safe, simple and needlefree vaccinations australia unlimited. Arc future fellow pioneers needlefree immunisation for. The company is working on boosting the performance of existing vaccines through.
Oct 05, 2017 efforts to rid the world of polio have taken another significant step. Needlefree nanopatch technology developed at the university of queensland has been used to successfully deliver an inactivated poliovirus vaccine. Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and nextgeneration vaccines with its proprietary hdmap technology platform, which uses an ultrahigh density array of projections invisible to the naked human eye applied to the skin to rapidly deliver vaccine to the abundant immune cells. Vaxxas is a privatelyheld biotechnology company focused on enhancing the performance of existing and next generation vaccines with its proprietary nanopatch technology platform. Nanopatch polio vaccine success uq news the university of. Vaxxas proprietary nanopatch platform induces robust immune system. Vaxxas nanopatch technology aims to provide an optimized, differentiated needlefree vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy. Vaxxas is developing an advanced platform for needlefree vaccine delivery. Invetech and vaxxas named recipients of the 2015 good. Bioengineer developing needlefree nanopatch vaccines reuters. Nanopatch contains a high density array of projections. Vaxxas is working on a new, less invasive vaccine delivery technology that creates a more potent immune response. We work closely as a team and thrive in a dynamic, exciting, and engaging work environment.
Vaxxas ceo david hoey says the company is seeking u. Nanopatchrevolutionising treatment of disease across the. Needlefree nanopatch vaccine delivery system news medical. Meet the technology pioneers of 2015 world economic forum. Vaxxas has pipeline projects with some of the largest vaccine manufacturers in the world as well as leading humanitarian organisations such as the world health. Application of the nanopatch to the skin is designed to be pain free, rapidly delivering vaccine directly to the abundant. I met david at the latest tedmed conference and spoke with him about his research and the direction vaxxas is pushing. We are extremely grateful to the who for providing funding to vaxxas pty ltd, the biotechnology company commercialising the nanopatch. Bioengineer developing needlefree nanopatch vaccines. Invetech and vaxxas named recipients of the 2015 good design.
Mark has had to push the science and business worlds to see the value of his new approach to vaccine delivery. Mark kendalls nanopatch could revolutionize infectious disease protection for milions globally. Vaxxas, a brisbane, australiabased company, develops and commercializes needlefree vaccine delivery system. In 2014 vaxxas signed an agreement with the world health organisation who to trial the nanopatch delivery system for polio vaccines. Needlefree vaccination and vaccine delivery solutions that safely and cost effectively amplify vaccine efficacy using nanopatch technology developed by. So mark went back to first principles and invented the nanopatch. The company is working on boosting the performance of existing vaccines through a novel vaccine delivery technology called nanopatch.
Vaxxas appoints david hoey as companys first ceo business wire. Nanopatch microprojections breach the stratum corneum and penetrate into the viable epidermis and dermis. Vaxxas, the biotech company kendall founded, drew millions in investment capital. Nov 19, 2014 nanopatch is the vaccine delivery system for people who fear needles. Revolutionizing vaccination vaxxas secures funding to advance clinical development of the nanopatch, a painfree, needlefree vaccine. Vaxxas nanopatch vaccine delivery system wearable technologies. The nextgeneration vaccine delivery system, created by vaxxas, is called the nanopatch and is the size of an adult thumbnail. The basics of the clinical trial pathway for a new vaccine delivery technology and the associated manufacturing and quality requirements will be discussed in a 1 hour seminar in the auditorium, followed by lunch in. The company offers vaccine coated microprojections that perforate into the outer layers of the skin when applied with an. Vaxxas nanopatch technology enables vaccination by briefly applying a small patch to the skin, offering a safer, painless and easier to use alternative to needle delivery. Oct 05, 2017 we are extremely grateful to the who for providing funding to vaxxas pty ltd, the biotechnology company commercialising the nanopatch.
Today, nanopatch is a developing technology that promises to make the. Vaxxas is disrupting and revolutionizing the way vaccines are delivered, through their innovative nanopatch. Vaxxas selected as world economic forum technology pioneer. Each nanopatch consists of a 16 mm 2 silicon base with 3364 microprojections 21, 025 cm. Related how wearable devices are changing the world of drug delivery. Advances in vaccine technology and their impact on managed care. A fresh study of the nanopatch a microscopic vaccine delivery platform has shown the device more effectively combats. In 2014, vaxxas was selected as a world economic forum technology. Vaxxas ceo mr david hoey said the first human vaccination studies are scheduled for this year.
Queensland biotechnology startup, vaxxas has formed a new partnership with queensland micro and nanotechnology centre qmnc at griffith university to help boost nanotechnology commercialisation. Efforts to rid the world of polio have taken another significant step. Vaxxas, which opened its local office two years ago and has its ceo here, was been named a 2015 technology pioneer today by the world economic forum for its. Vaxxas biomedical expertise to boost griffith microtech.
Aug 02, 2011 the nanopatch also offers a way to stop needlestick injuries during vaccination which again is a particularly important problem in africa. This most recent study showed the nanopatch enhanced responses to all three types of inactivated poliovirus vaccines ipv a necessary advancement from using the current live oral vaccine. University of queensland sanice embleton february 10, 2015 vaxxas, paul kelly. Jun, 20 the patent looked almost identical to the needles we use today. Vaxxas, a clinicalstage biotechnology company commercializing a novel vaccination platform, today announced the publication in the journal plos medicine of groundbreaking clinical research indicating the broad immunological and commercial potential of vaxxas novel highdensity microarray patch hdmap. Vaxxas nanopatch is novel, cost effective and safe vaccine delivery system vaxxas, a brisbane, australiabased company, develops and commercializes needlefree vaccine delivery system. Vaxxas was incorporated in 2011 and is based in brisbane, australia. Vaccinations have historically been given using syringes and needles.
Sep 16, 2014 vaxxas is a privatelyheld biotechnology company focused on enhancing the performance of existing and nextgeneration vaccines with its proprietary nanopatch technology platform. The nanopatch is comprised of an ultrahigh density array of very short projections invisible to the naked eye that are coated with vaccine. Vaxxas initiates research project on advancing next. Needlefree vaccination and vaccine delivery solutions that safely and cost effectively amplify vaccine efficacy using nanopatch technology developed by vaxxas. Nanopatch for effective, painfree vaccine delivery. Vaxxas is a privatelyheld biotechnology company focused on enhancing the performance of existing and nextgeneration vaccines with its proprietary nanopatch technology platform. News vaxxas initiates research project on advancing next. Vaxxas publication in plos medicine reveals groundbreaking. Oct 09, 2012 vaxxas appoints david hoey as ceo, initiates collaboration with merck. The nanopatch is designed to deposit vaccine antigens just under the surface of the skin, amongst the dense populations of immune cells. Vaxxas appoints david hoey as ceo, initiates collaboration with merck. David hoey is the ceo and director of the vaxxas, a company working on. Vaxxas is developing what its calling the nanopatch, a halfinch square, needlefree method of vaccinating that would also be easier to transport because it doesnt need refrigeration. Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and nextgeneration vaccines with its proprietary hdmap technology.
After 160 years, its time to throw away the needle and syringe. Vaxxas appoints david hoey as ceo, initiates collaboration. Drycoated live viral vector vaccines delivered by nanopatch. Vaxxas designed the silicone patch to allow the vaccine to coat it uniformly and consistently. The vaxxas nanopatch jet coating instrument is an advanced technology platform to support needlefree dermal drug delivery research and product development. Initial tests were required on a vaccinefree nanopatch just to determine if. Vaxess is building a diverse team of exceptional people to rapidly advance innovative therapies on the mimix platform.
Revolutionizing vaccination vaxxas secures funding to advance clinical development of the nanopatch, a painfree, needlefree vaccine application and delivery system. Professor kendalls research and development has led to the university of queensland spinout biotechnology company, vaxxas. Vaxxas has just signed an agreement with the world health organisation who to trial its nanopatch delivery system for polio vaccines, which the company hopes will progress the technology. Invetech and vaxxas named recipients of the 2015 good design award for development of nanopatch jet coating instrument for needlefree drug delivery. Because it delivers the active ingredient right to where it is needed, tests have. Vaxxas looks to enhance the performance of existing and next generation vaccines with its proprietary nanopatch technology platform. Merck acquires license for experimental skinpatch immunization. However, most vaccines in use today were developed by techniques that were pioneered more than 100 years ago and do not represent the full potential of the field. On the 23rd august vaxxas will present an overview of the company, the nanopatch technology and translation activities to date. They were instrumental in helping to design and manufacture the tiny 1cm. In recent exciting news, vaxxas, on 16 september 2014, signed an agreement with the world health organisation to trial the nanopatch delivery system for polio vaccinesit is hoped this agreement will assist to move the technology through the next stage of clinical trials. The australian firms nanopatch consists of thousands of microprojectors invisible to the naked eye which deliver vaccine material just beneath the outer skin layer. The nanopatch is solid and not dissolvable and consists of a pucklike device containing an integrated applicator and the map.
1375 1436 1010 406 231 1344 1365 1262 1445 1223 14 10 642 1082 571 1476 383 82 674 800 973 1363 1243 207 849 156 494 1437 1011 1007 601 901 510 266 937 1377